On June 1, 2022 EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical-stage biopharmaceutical company with a mission to enhance the therapeutic efficacy of medicines through ultrasound-mediated drug delivery, reported the presentation of preclinical results of Acoustic Cluster Therapy (ACT) in a murine brain model, at the Annual International Symposium for Therapeutic Ultrasound (ISTU) Conference being held on 7th -10th June 2022 in Toronto, Canada (Press release, Exact Therapeutics, JUN 1, 2022, View Source [SID1234615347]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ISTU is a non-profit organization founded in 2001 to increase and diffuse the knowledge of therapeutic ultrasound to the scientific and medical community and facilitate the translation of therapeutic ultrasound techniques into the clinical area for the benefit of patients worldwide.

The work presented by EXACT-Tx at the ISTU demonstrates the possibility of using ACT to help deliver therapeutics to the brain, addressing a significant unmet medical need with close to 98% of drugs in development unable to cross the blood-brain barrier (BBB).

Dr Masha Strømme, Executive Chair EXACT-Tx said: "These data sets have deepened our understanding of the mechanism behind ACT-induced increased BBB permeability and enhanced accumulation of co-injected molecules, and also given us new insights on the spatial and temporal extravasation pattern induced by ACT, important for understanding the mechanism of this therapeutic strategy for drug delivery to the brain."